Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji 670-8524, Japan.
Mol Med Rep. 2012 Mar;5(3):603-9. doi: 10.3892/mmr.2011.734. Epub 2011 Dec 22.
The effects of 9 calcium antagonists on ABCG2/BCRP-mediated resistance and transport were examined in HeLa and SN-38-resistant HeLa (HeLa/SN100) cells, overexpressing ABCG2/BCRP. Sensitivity to mitoxantrone, an ABCG2/BCRP substrate, in HeLa/SN100 cells was significantly reversed by the coexistence of the calcium antagonists, except for diltiazem and verapamil. The accelerated transport activity of Hoechst33342, an ABCG2/BCRP substrate, in HeLa/SN100 cells was significantly decreased by the presence of the calcium antagonists, except for diltiazem, nifedipine or verapamil, returning to the level of HeLa cells. The present study classifies the calcium antagonists into 3 categories: strong (benidipine, felodipine, nicardipine, nisoldipine and nitrendipine), moderate (amlodipine and nifedipine) and weak (diltiazem and verapamil) inhibitors of ABCG2/BCRP.
研究了 9 种钙拮抗剂对 ABCG2/BCRP 介导的耐药性和转运的影响,这些钙拮抗剂在过表达 ABCG2/BCRP 的 HeLa 和 SN-38 耐药的 HeLa(HeLa/SN100)细胞中进行了研究。在 HeLa/SN100 细胞中,米托蒽醌(ABCG2/BCRP 的底物)的敏感性与钙拮抗剂的共存显著逆转,除了地尔硫卓和维拉帕米。Hoechst33342(ABCG2/BCRP 的底物)在 HeLa/SN100 细胞中的加速转运活性,除了地尔硫卓、硝苯地平和维拉帕米外,均明显降低,恢复到 HeLa 细胞的水平。本研究将钙拮抗剂分为 3 类:强抑制剂(贝尼地平、非洛地平、尼卡地平、尼索地平、硝苯地平)、中效抑制剂(氨氯地平和硝苯地平)和弱抑制剂(地尔硫卓和维拉帕米)。